Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer
Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined....